



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/613,335	07/03/2003	Walter A. Zohmann	10012.7	5090
21999 7590 11/09/2009 KIRTON AND MCCONKIE 60 EAST SOUTH TEMPLE, SUITE 1800 SALT LAKE CITY, UT 84111				
EXAMINER CAMPBELL, VICTORIA P				
ART UNIT		PAPER NUMBER		
3763				
MAIL DATE		DELIVERY MODE		
11/09/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/613,335

Applicant(s)

ZOHMANN, WALTER A.

Examiner

VICTORIA P. CAMPBELL

Art Unit

3763

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 August 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SF/ICE)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

This is the second Office Action following the Request for Continued Examination based on the 10/613335 application filed July 3, 2003. Claims 1-9 as amended August 3, 2009 are currently pending and considered below.

Response to Amendment

1. In light of applicant's amendments to the claims, the previous rejections under 35 U.S.C. 112, first and second paragraph are withdrawn.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

4. Claims 1, 2, and 7-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over USPN 5,250,035 to Smith et al in view of USPGPub 2002/0123723 to Sorenson et al.

Regarding the above claims, Smith et al teach a hollow needle (28), a needle hub (32) having a hollow interior (38) at the proximate end of the hollow needle (34), and a stylet cap (60) on a proximal end of a stylet (68), the stylet being freely movable within the needle (Col. 4, lines 43-45), wherein the stylet cap creates a releasably secure fit with the needle hub (66 received into 38). Smith et al also teach the process of identifying the dermal area of the patient (Col. 3, lines 27-29), inserting and advancing the needle into the dermal area (Col. 4, lines 63-67), withdrawing the stylet (Col. 5, lines 6-8), and injecting an anesthetic (Col. 4, lines 58-60), wherein the needle further comprises a needle hub (32), and wherein withdrawal of the stylet comprising observing a backflow of fluid (Col. 5, lines 8-15).

Smith et al fail to teach or disclose the hollow needle having a plurality of fenestrations longitudinally disposed along alternate sides of the needle, within 0.17 inches of the distal end. However, Sorenson et al teach a plurality of fenestrations (85) disposed on alternate sides of the needle (Fig. 1) at the distal delivery portion of the device (50), which "may extend any suitable predetermined length from the distal end 45 toward the proximal end 42 of the tubular element 25" which the examiner believes includes a length of 0.17 inches based on the intended use of the device (Paragraph [0027]).

Smith et al and Sorenson et al are analogous art because they are from the same field of endeavor/problem solving area of medical needles. At the time of the invention, it would have been obvious to one of ordinary skill in the art, having the teachings of Smith et al and Sorenson et al before him or her to modify the needle of Smith et al to include the multiple distally located apertures of Sorenson et al because doing so provides a wider distribution of fluid than with a single opening while still limiting distribution to a treatment site (Sorenson et al, Paragraphs [0033] and [0036]). Therefore, it would have been obvious to combine Smith et al with Sorenson et al to obtain the invention in the instant claims.

5. Claims 3-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith et al and Sorenson et al in further view of USPGPub 2002/055715 to Young et al.

Regarding claims 3 and 4, Smith et al and Sorenson et al disclose the invention of claims 1 and 2 as described above, but fail to teach or disclose a fenestration indicator or a magnifying window on the needle hub. However, Young et al teach a needle hub (10) containing both a fenestration indicator (16) and a magnifier (17).

Regarding claims 5 and 6, Smith et al teach a hollow needle (28) being bounded by an occluded tip (72), a needle hub (32) at the proximate end of the hollow needle (34), and a stylet cap (60) on a proximal end of a stylet (68), wherein the stylet cap creates a releasably secure fit with the needle hub (66 received into 38), the stylet being freely movable within the needle (Col. 4, lines 43-45), wherein the stylet occludes the fenestrations (Fig. 11).

Smith et al fail to teach the needle having a plurality of longitudinally disposed fenestrations. Smith et al also fail to teach the needle hub having at least one fenestration indicator and a magnifying window.

Sorenson et al teach a plurality of fenestrations (85) disposed on alternate sides of the needle (Fig. 1). Combination of Smith et al and Sorenson et al is reasoned above.

Young et al teach a needle hub (10) containing both a fenestration indicator (16) and a magnifier (17).

Smith et al, Sorenson et al, and Young et al are analogous art because they are from the same field of endeavor/problem solving area of medical needles. At the time of the invention, it would have been obvious to one of ordinary skill in the art, having the teachings of Smith et al, Sorenson et al, and Young et al before him or her to modify the needle system of Smith et al and Sorenson et al to include the fenestration indicator and magnifying window of Young et al because the indicator allows the user to properly orient the hub during low light conditions (Young et al, Paragraph [0031]) and the magnifier decreases the recognition time from when the fluid first enters the hub (Young et al, Abstract). Therefore, it would have been obvious to combine Smith et al and Sorenson et al with Young et al to obtain the invention in the instant claims.

Response to Arguments

6. Applicant's arguments filed August 3, 2009 regarding claims 1-9 have been fully considered but they are not persuasive.

7. Regarding applicant's argument that one having ordinary skill in the art would not be motivated to design a needle having the fenestrations located within the most distal 0.17 inches based on the teachings of Smith et al and Sorenson et al, the examiner disagrees. The examiner notes, in addition to disclosing that the fenestrations of Sorenson et al can be dispersed along any length of needle necessary for proper treatment of the patient, which would differ based on injection site and intended therapy, that the illustrated embodiment of Sorenson et al is a non-limiting example intended to showcase a particular use of the device. Furthermore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to choose the value of 0.17 inches for the intended use of injection in a fascial compartment, since it has been held that discovering an optimum value of a result effective variable involves only routine skill in the art. *In re Boesch*, 617 F.2d 272, 205 USPQ 215 (CCPA 1980).

8. Regarding applicant's argument that Sorenson et al disclose a method of distributing medicine along the *entire length* of a needle, and therefore outside of the desired treatment area, the examiner disagrees and draws applicant's attention to Paragraph [0027] of Sorenson et al which discloses that the delivery area (50) can extend any length beginning at the distal tip and extending as far as the proximal end of the delivery tube. This includes the extreme distal end, the entire length of the tube, and all potential measurements in between. Both applicant and Sorenson et al have the same goal, to "maximize an even distribution" of medication to a treatment site. Further, the portion of Sorenson quoted by applicant on Page 7, Paragraph 1 of the arguments filed August 3, 2009, bolsters this idea: Sorenson's goal is to introduce

medication to a treatment site "larger than the absorption field immediately surrounding the discharge orifice of a needle or catheter" [0011] which corresponds to applicant's own statement that the plurality of fenestrations "facilitate even distribution of local anesthetic to an affected peripheral nerve." (Instant specification; Page 8, lines 16-17).

Conclusion

9. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **VICTORIA P. CAMPBELL** whose telephone number is (571)270-5035. The examiner can normally be reached on **Monday-Thursday, 7-5:30.**

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas Lucchesi can be reached on 571-272-4977. The fax phone

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Victoria P Campbell
Examiner, AU 3763

/Nicholas D Lucchesi/
Supervisory Patent Examiner, Art Unit 3763